(Q37976540)

26 August 2017

title

Adjuvanted influenza vaccines. (English)

1 reference

26 August 2017

2

1 reference

26 August 2017

1

Nicola Principi

1 reference

26 August 2017

publication date

1 January 2012

1 reference

Human Vaccines & Immunotherapeutics

26 August 2017

published in

1 reference

26 August 2017

volume

8

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

59-66

1 reference

Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Socioeconomic impact of influenza on healthy children and their families

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

The global state of influenza in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Present and future of influenza prevention in pediatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Unmet needs in modern vaccinology: adjuvants to improve the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

On the relationship between mean antibody level, seroprotection and clinical protection from influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Vaccine adjuvants: putting innate immunity to work

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

21 January 2018

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

A study of Gulf War veterans with a possible deployment-related syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Vaccination, squalene and anti-squalene antibodies: facts or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

The virosome concept for influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

The virosomal adjuvanted influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

IgG2a restriction of murine antibodies elicited by viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

The immunoglobulin G subclass responses of mice to influenza A virus: the effect of mouse strain, and the neutralizing abilities of individual protein A-purified subclass antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

The role of adjuvants in vaccines for seasonal and pandemic influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

Development and evaluation of influenza pandemic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18011

21 January 2018

Identifiers

DOI

10.4161/HV.8.1.18011

1 reference

26 August 2017

1 reference